As Korea rapidly emerges as a global hub for ADC innovation, the inaugural World TPD & Induced Proximity Summit South Korea is the first and only industry-led meeting point for companies looking to accelerate development, forge cross‑regional partnerships, and strengthen their competitive position. Bringing together leading experts from R&D, CMC, clinical development, and business strategy, the summit is the one event no TPD stakeholder can afford to miss.
Why is 2026 the Breakout Year for PROTACs & Molecular Glues?
2026 is set to be the most transformative year yet for targeted protein degradation (TPD). With the first anticipated PROTAC approval and multiple degraders advancing through Phase 1 and Phase 2 clinical trials, the field is shifting decisively from promise to clinical reality.
This milestone is catalyzing a broader surge in global investment and accelerating demand for translational expertise, scalable platforms, and new approaches to induced proximity.
South Korea: A Rapidly Emerging TPD Hub
Nowhere is the industry momentum more evident than in South Korea, which has rapidly emerged as a leading hub for next‑generation TPD innovation with:
- Over $144M raised in the last 12 months
- Strong foundation of world‑class chemistry expertise
- Fast‑moving biotech startups advancing novel degrader pipelines
- Global pharma engagement accelerating collaborations and investment
Key companies driving this growth include:
- Ubix Therapeutics
- Prazer Therapeutics
- AUTOTAC Bio
These innovators are progressing programs from early discovery into translational and early clinical stages, supported by expanding platform technologies, AI‑enabled discovery approaches, and advanced proteomics capabilities.
Expanding the Degrader Toolbox
As the degrader landscape diversifies, developers now have an increasingly sophisticated toolkit at their disposal:
- PROTACs
- Molecular glues
- Novel E3 ligase approaches
- DACs
- Ubiquitin‑independent degradation mechanisms
With this expansion, R&D teams are prioritizing:
- Improving selectivity
- Optimizing PK/PD
- Establishing clinically viable and globally competitive candidates
Why Attend the World TPD & Induced Proximity Summit South Korea?
The inaugural World TPD & Induced Proximity Summit South Korea launches at a defining moment for the field, taking place in Seoul, which is considered Asia’s most active innovation hub, with capital, talent, and platform technologies converging at unprecedented speed. This meeting stands as the Asia's only meeting dedicated to end‑to‑end TPD drug development, bringing together experts across discovery, translational development, and early clinical strategy.
Attendees will hear from global leaders including Astellas, Amgen, FIMECS, BeOne Medicines, Degron Therapeutics, Tanabe Pharma, and more across the full R&D ecosystem.
The program will allow you to:
- Benchmark emerging clinical expectations: Understanding how first‑in‑class degradation programs are shaping regulatory and clinical pathways
- Integrate proteomics and AI into TPD workflows: See how leading organizations are embedding data‑driven discovery into degrader development
- Evaluate cutting‑edge degrader data across PROTACs, molecular glues, DACs, induced proximity platforms, and next‑gen E3 ligases
Whether you’re advancing internal degrader programs, evaluating partnerships, or mapping out your 2026 strategy, this is the moment, and Seoul is the place to be. Download the full event guide to learn more.
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.